TNFRSF9 and neoplasm: IBI319, a CD137/PD‐1 bispecific antibody developed by Innovent Biologics, can enhance the anti‐tumor efficacy of PD‐1 blockade without causing hepatotoxicity in CT26 and MC38 tumor models.